PD2M AI For Pharma Conference Session Topics

Application of Artificial Intelligence (AI) and Machine Learning (ML) to Discovery of Biological Therapeutics

Artificial Intelligence (AI) and Machine Learning (ML) have redefined biologics drug discovery process from target identification to candidate generation, lead optimization, property prediction and optimization. The AI driven computational models are also combined with experimental data in a “Lab-in-the-loop” approach to drive continuous drug improvements and accelerate the  discovery of new medicines.
Speakers will showcase practical case studies in several aspects of drug discovery using AI/ML tools, such as generative AI for molecular design, knowledge extraction and summarization, AI models to predict clone performance, productivity and stability, multi-modal data modeling to drive process improvements with Lab-in-the-loop concept.

Application of Artificial Intelligence (AI) and Machine Learning (ML) to Discovery of Small Molecule Therapeutics

Recent advances in artificial intelligence are reshaping molecular discovery workflows. This session will explore applications of state-of-the-art AI methodologies to small molecule drug discovery, including generative models, models for property prediction, and multi-objective optimization strategies. Presentations will highlight opportunities and challenges in bringing AI tools to bear on real-world discovery problems.

Integration of Artificial Intelligence (AI) and Machine Learning (ML) into drug substance process development and manufacturing

The integration of Artificial Intelligence (AI) and Machine Learning (ML) into drug substance process development and manufacturing is reshaping how we design, scale, and deliver biopharmaceutical products. This session will explore cutting-edge applications of AI/ML that are enabling more efficient process optimization, accelerating tech transfer, improving quality, and driving innovation in both drug substance process development and manufacturing operations. Speakers will showcase practical case studies demonstrating how AI/ML tools are being integrated into process development workflows to shorten cycle times, augment decision making, optimize process design, and ensure right first-time tech transfers. Discussions of challenges and  onsiderations to implementation of AI/ML into GxP manufacturing operations is also encouraged.

The session will bring together scientists, engineers, technology leaders, and business professionals to share experiences and perspectives on harnessing AI/ML for drug substance process development and manufacturing. We hope to encourage open dialogue on opportunities, challenges, and future directions, creating a unique space for networking and partnership.

Whether you are a process development profession discovering how AI can accelerate your work or a data scientist adapting existing AI tools for drug substance operations, this session will provide fresh insights and action strategies for further adoption of AI/ML.

Transforming Drug Product Development and Manufacturing with AI

AI is one of the defining mega trends of our time, reshaping industries from finance to transportation—and now transforming how medicines are developed and manufactured. The pharmaceutical industry is rapidly adopting artificial intelligence to accelerate and de-risk drug product (DP) development and to design and optimize DP manufacturing processes. This session will highlight cutting-edge applications of AI from accelerating formulation design and predictive modeling to enabling smarter scale-up, tech transfer and adaptive manufacturing across all modalities. Case studies will highlight both the opportunities and the challenges, including data readiness, regulatory considerations, and cultural adoption hurdles. The goal of this session is to provide attendees with concrete examples of how AI is transforming drug product process development and manufacturing and to inspire ideas for new opportunities in this space.

Regulatory Panel

This panel discussion will bring together current and former regulatory agency leaders to examine how artificial intelligence is reshaping regulatory expectations, review processes, and industry-regulator interactions in the pharmaceutical industry.

External Perspectives Panel

This panel discussion features experts working at the cutting edge of artificial intelligence and autonomous laboratory systems who will offer their insights into emerging capabilities and discuss where these tools can be most effectively deployed across pharmaceutical development and manufacturing.